Vimarsana
Biggest News Aggregation in the World

Aimmax Therapeutics News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Aimmax Therapeutics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Aimmax Therapeutics Today - Breaking & Trending Today

APP13007 Emerging Drug Insights and Market Forecasts, 2019-2032: Focus on United States, Germany, France, Italy, Spain, United Kingdom, Canada and South Korea - Vimarsana News

APP13007 Emerging Drug Insights and Market Forecasts, 2019-2032: Focus on United States, Germany, France, Italy, Spain, United Kingdom, Canada and South Korea

/PRNewswire/ -- The "APP13007 Emerging Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering. This report...

Formosa Pharmaceuticals and AimMax Therapeutics Announce the NDA Submission to the US FDA for APP13007 for the Treatment of Post-Operative Inflammation and Pain following Ocular Surgery - Vimarsana News

Formosa Pharmaceuticals and AimMax Therapeutics Announce the NDA Submission to the US FDA for APP13007 for the Treatment of Post-Operative Inflammation and Pain following Ocular Surgery

/PRNewswire/ -- Formosa Pharmaceuticals, Inc. (6838.TWO) and AimMax Therapeutics, Inc. (United States) announce the submission of a New Drug Application to the...

Formosa Pharmaceuticals and AimMax Therapeutics Announce Successful Top-Line Results from CPN-302 for the Treatment of Inflammation and Pain after Cataract Surgery. - Vimarsana News

Formosa Pharmaceuticals and AimMax Therapeutics Announce Successful Top-Line Results from CPN-302 for the Treatment of Inflammation and Pain after Cataract Surgery.

/PRNewswire/ -- Formosa Pharmaceuticals, Inc. (6838.TWO) and AimMax Therapeutics, Inc. (United States) report successful top-line results from CPN-302, the...

Taiwan strengthens treatment offering for inflammation and pain after cataract surgery - Vimarsana News

Taiwan strengthens treatment offering for inflammation and pain after cataract surgery

Formosa Pharmaceuticals and AimMax Therapeutics announced positive results of ophthalmic drug

Formosa Pharmaceuticals and AimMax Therapeutics Announce Successful Top-Line Results from CPN-301 for the Treatment of Inflammation and Pain after Cataract Surgery - Vimarsana News

Formosa Pharmaceuticals and AimMax Therapeutics Announce Successful Top-Line Results from CPN-301 for the Treatment of Inflammation and Pain after Cataract Surgery

/PRNewswire/ -- Formosa Pharmaceuticals, Inc. (TWO.6838) and AimMax Therapeutics, Inc. (United States) report successful top-line results from CPN-301, the...